Literature DB >> 14559957

Unique lipoprotein phenotype and genotype associated with exceptional longevity.

Nir Barzilai1, Gil Atzmon, Clyde Schechter, Ernst J Schaefer, Adrienne L Cupples, Richard Lipton, Suzanne Cheng, Alan R Shuldiner.   

Abstract

CONTEXT: Individuals with exceptional longevity have a lower incidence and/or significant delay in the onset of age-related disease, and their family members may inherit biological factors that modulate aging processes and disease susceptibility.
OBJECTIVE: To identify specific biological and genetic factors that are associated with or reliably define a human longevity phenotype. DESIGN, SETTING, AND PARTICIPANTS: In a case-control design, 213 Ashkenazi Jewish probands with exceptional longevity (mean [SD] age, 98.2 [5.3] years) and their offspring (n = 216; mean [SD] age, 68.3 [6.7] years) were recruited from 1998 to 2002, while an age-matched control group of Ashkenazi Jews (n = 258) and participants from the Framingham Offspring Study (n = 589) were accepted as control groups. MAIN OUTCOME MEASURES: Detailed questionnaires, physical examination, and blood samples were taken, including assessment of lipids and lipoprotein subclass levels and particle sizes by proton nuclear magnetic resonance. Samples were also genotyped for the codon 405 isoleucine to valine (I405V) variation in the cholesteryl ester transfer protein (CETP) gene, which is involved in regulation of lipoprotein and its particle sizes.
RESULTS: High-density lipoprotein (HDL) and low-density lipoprotein (LDL) particle sizes were significantly higher in probands compared with both control groups (P =.001 for both), independent of plasma levels of HDL and LDL cholesterol and apolipoprotein A1 and B. This phenotype was also typical of the proband's offspring but not of the age-matched controls. The HDL and LDL particle sizes were significantly larger in offspring and controls without hypertension or cardiovascular disease, (P =.001 and P =.008, respectively). Furthermore, lipoprotein particle sizes, but not plasma LDL levels, were significantly higher in offspring and controls without the metabolic syndrome (P<.001). Probands and offspring had a 2.9- and 3.6-fold (in men) and 2.7- and 1.5-fold (in women) increased frequency, respectively, of homozygosity for the 405 valine allele of CETP (VV genotype), respectively, compared with controls (P<.001 for both). Those probands with the VV genotype had increased lipoprotein sizes and lower serum CETP concentrations.
CONCLUSIONS: Individuals with exceptional longevity and their offspring have significantly larger HDL and LDL particle sizes. This phenotype is associated with a lower prevalence of hypertension, cardiovascular disease, the metabolic syndrome, and increased homozygosity for the I405V variant in CETP. These findings suggest that lipoprotein particle sizes are heritable and promote a healthy aging phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559957     DOI: 10.1001/jama.290.15.2030

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  203 in total

1.  Motoric cognitive risk syndrome: Multicenter incidence study.

Authors:  Joe Verghese; Emmeline Ayers; Nir Barzilai; David A Bennett; Aron S Buchman; Roee Holtzer; Mindy J Katz; Richard B Lipton; Cuiling Wang
Journal:  Neurology       Date:  2014-10-31       Impact factor: 9.910

2.  Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance.

Authors:  Brian A Irving; K Sreekumaran Nair; Manivannan Srinivasan
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

Review 3.  From genes to societies.

Authors:  Olav Rueppell; Gro V Amdam; Robert E Page; James R Carey
Journal:  Sci Aging Knowledge Environ       Date:  2004-02-04

4.  Is good cholesterol always good?

Authors:  Gilbert R Thompson
Journal:  BMJ       Date:  2004-08-28

5.  Evidence from case-control and longitudinal studies supports associations of genetic variation in APOE, CETP, and IL6 with human longevity.

Authors:  Mette Soerensen; Serena Dato; Qihua Tan; Mikael Thinggaard; Rabea Kleindorp; Marian Beekman; H Eka D Suchiman; Rune Jacobsen; Matt McGue; Tinna Stevnsner; Vilhelm A Bohr; Anton J M de Craen; Rudi G J Westendorp; Stefan Schreiber; P Eline Slagboom; Almut Nebel; James W Vaupel; Kaare Christensen; Lene Christiansen
Journal:  Age (Dordr)       Date:  2012-01-12

6.  Genomics of human health and aging.

Authors:  Alexander M Kulminski; Irina Culminskaya
Journal:  Age (Dordr)       Date:  2011-12-16

7.  Age editorial.

Authors:  Bradley J Willcox
Journal:  Age (Dordr)       Date:  2006-11-18

8.  Distinguishing between longevity and buffered-deleterious genotypes for exceptional human longevity: the case of the MTP gene.

Authors:  Derek M Huffman; Joris Deelen; Kenny Ye; Aviv Bergman; Eline P Slagboom; Nir Barzilai; Gil Atzmon
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-04-10       Impact factor: 6.053

9.  FOXO3 gene variants and human aging: coding variants may not be key players.

Authors:  Timothy A Donlon; J David Curb; Qimei He; John S Grove; Kamal H Masaki; Beatriz Rodriguez; Ayako Elliott; D Craig Willcox; Bradley J Willcox
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-28       Impact factor: 6.053

10.  Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.

Authors:  Gina M Peloso; Serkalem Demissie; Dorothea Collins; Daniel B Mirel; Stacey B Gabriel; L Adrienne Cupples; Sander J Robins; Ernst J Schaefer; Margaret E Brousseau
Journal:  J Lipid Res       Date:  2010-09-20       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.